Chemotherapy Drugs in India: Classes, Handling and Access

This guide to chemotherapy drugs India stocks covers the major classes a hospital pharmacy handles, why cytotoxic drugs need handling protocols ordinary medicines don't, what NPPA price control actually covers, Jan Aushadhi generic access, and where biosimilars fit into cost.

What are platinum-based chemotherapy drugs like cisplatin and carboplatin?

Cisplatin and carboplatin are platinum-coordination compounds. They damage cancer cell DNA by forming cross-links that block replication, and they remain first-line therapy for ovarian, cervical, lung, head and neck, bladder and testicular cancers in Indian oncology practice. Both are old, cheap-to-make drugs by cancer-drug standards. Yet a 2026 shortage in raw platinum inputs pushed the government to intervene on pricing.

NPPA raised the ceiling price of cisplatin from ₹7.26 to ₹10.89 per ml, and carboplatin from ₹60.49 to ₹90.74 per ml. That is a 50% one-time increase, notified on 11 June 2026 under Paragraph 19 of the Drug Price Control Order 2013, a clause that lets the authority override a fixed ceiling in the public interest Business Standard. Manufacturers had said production was no longer viable at the old ceiling.

For a hospital pharmacy, that notification is a warning. A formulary built around last year's ceiling price can be wrong within a quarter. Procurement teams tracking chemotherapy drugs India relies on daily need to watch NPPA notifications for these two molecules specifically, not assume DPCO ceilings hold indefinitely.

What are taxanes and where does paclitaxel fit in Indian chemotherapy protocols?

Taxanes, chiefly paclitaxel and docetaxel, stabilise microtubules so cancer cells cannot finish dividing. They anchor breast, ovarian, lung and head-and-neck regimens across Indian oncology centres. Unlike platinum agents, taxanes are formulated in solvents that carry their own infusion-reaction risk, and that shapes how a pharmacy prepares and dispenses them.

Several Indian manufacturers produce paclitaxel domestically alongside imported branded versions. That gives hospitals a real choice between originator and generic taxane products, rather than dependence on one supplier. Taxane pricing has stayed comparatively steadier than the platinum-agent shortage produced in 2026. Supply still depends partly on active pharmaceutical ingredient imports from China.

Stocking a taxane means having infusion sets and premedication ready alongside the vial. Paclitaxel's solvent carrier is linked to hypersensitivity reactions, so antihistamine and steroid premedication is standard before administration. That is a preparation step, not just an inventory line.

What are anthracyclines and why does doxorubicin need special handling?

Anthracyclines, led by doxorubicin, slot into DNA and block topoisomerase II, killing rapidly dividing cells across breast cancer, lymphoma and several paediatric cancers treated in India. Doxorubicin carries a well-documented cumulative cardiotoxicity risk. A patient's lifetime dose across every treatment line has to be tracked, more so than with most other chemotherapy classes.

Doxorubicin is also a vesicant. It causes severe local tissue damage if it leaks outside a vein during infusion. Extravasation protocols, dedicated staff training and ready access to antidotes are standard wherever it is stocked, following the same hazardous-drug handling framework that applies to cytotoxic agents generally under occupational safety guidance for hospital pharmacies PMC. A hospital dispensing doxorubicin needs nursing staff trained on this before the drug ever leaves the shelf.

Liposomal doxorubicin, a reformulated version with lower cardiotoxicity, is also made and sold in India. It gives oncologists an option for patients who have already accumulated a meaningful anthracycline dose from earlier treatment.

Why do cytotoxic chemotherapy drugs need specialised hospital pharmacy handling?

Cytotoxic drugs are classed as hazardous because they show genotoxicity, carcinogenicity in animal models, or organ toxicity at low exposure. Staff preparing and administering them face real occupational risk, not just the patients receiving them. Studies of nurses and pharmacy staff handling cytotoxic drugs without proper controls have reported elevated chromosomal changes linked to chronic low-level exposure during preparation and spill cleanup PMC.

Under India's Bio-Medical Waste Management Rules, discarded cytotoxic drugs fall into a distinct waste category. They must be incinerated above 1,200°C or returned to the manufacturer, never mixed with general pharmaceutical waste CPCB. Transport containers need visible hazard labelling. Spill kits need to sit wherever these drugs are stored or reconstituted.

Oncology drug storage cannot be an extension of a hospital's general pharmacy shelf. Cold-chain reliability, negative-pressure preparation areas, personal protective equipment and a documented chain of custody from receipt to disposal are operational requirements. They are not refinements a facility adds later.

Does NPPA price control actually cover chemotherapy drugs in India?

Partially, and unevenly. NPPA capped trade margins on 42 non-scheduled anti-cancer drugs at 30% in February 2019, its first use of a "Trade Margin Rationalisation" approach. Afterward, 526 brands of those drugs cut prices by up to 90%, including one erlotinib brand that fell from ₹9,999 to ₹891.79 per pack PIB.

That 2019 action targeted non-scheduled drugs specifically: molecules outside the DPCO's formal ceiling schedule that were still showing steep markups. Scheduled molecules like cisplatin and carboplatin follow a different mechanism, a fixed ceiling price NPPA can revise up or down, as the 2026 platinum-agent increase shows. A pharmacy cannot assume every chemotherapy drug India stocks follows one uniform pricing regime.

The practical takeaway matches other price-controlled categories. A ceiling or margin cap fixes one number for one named formulation and pack size. A different strength, a combination product, or a molecule NPPA has not yet scheduled sits entirely outside it.

What does Jan Aushadhi generic access look like for chemotherapy drugs?

Jan Aushadhi generic anticancer drugs cost less than branded equivalents in 26 of 27 molecules studied in a peer-reviewed cost comparison. Doxorubicin 50mg showed the widest gap, up to 34 times cheaper than the costliest branded version, and docetaxel showed the largest rupee saving, around ₹16,000 per course component PMC. Methotrexate 2.5mg was the one exception.

The study covered 19 cytotoxic drugs, five hormone modulators, two immune modulators and one bisphosphonate — most of the chemotherapy classes an Indian oncology unit actually stocks. Fluorouracil injection, a backbone drug for gastrointestinal and head-and-neck cancers, sits on the Pradhan Mantri Bhartiya Janaushadhi Pariyojana price schedule at roughly ₹11.50 per 500mg/10ml vial.

For a hospital treating meaningful cancer volume, sourcing generic chemotherapy backbone drugs through Jan Aushadhi channels, where clinically appropriate, cuts per-cycle cost without changing the protocol itself.

Are biosimilar oncology drugs available in India?

Yes. India approved biosimilar monoclonal antibodies for cancer years ahead of many Western regulators. CDSCO has cleared biosimilar rituximab, trastuzumab and bevacizumab, and roughly three-quarters of all CDSCO-approved biosimilars serve oncology and its supportive care BioSpectrum India. Dr. Reddy's Reditux, a rituximab biosimilar, along with its later Hervycta and Versavo products, were among the earliest to reach Indian practice.

Biosimilars mostly sit downstream of chemotherapy. They layer on top of a cytotoxic backbone rather than replacing platinum agents, taxanes or anthracyclines outright. But they matter to cost, because monoclonal antibody therapy is where a single course can otherwise run into lakhs of rupees. A hospital offering a CDSCO-approved biosimilar alongside chemotherapy gives patients a regulator-approved lower-cost path instead of a choice between originator biologic and nothing.

Uptake still varies by hospital and by which manufacturer relationships a pharmacy has built. That is one more reason oncology procurement needs a deliberate formulary decision, not whichever product a visiting representative is selling that month.

Chemotherapy drugs are not a category a hospital pharmacy can stock casually. Platinum agents, taxanes and anthracyclines each carry distinct storage and disposal requirements. Cytotoxic protocols demand trained staff and dedicated preparation space. Pricing on molecules like cisplatin and carboplatin can shift by regulatory notification rather than market forces alone. A pharmacy that cannot guarantee reliable in-house stocking of the specific regimen a patient is already on sends that patient elsewhere mid-treatment, at exactly the point where continuity and dosing-schedule adherence matter most. Medyzen's guides on managed hospital pharmacy services, pharmacy inventory management for expiry and dead stock, and branded versus generic medicine margins cover how formulary discipline and cold-chain-aware inventory support this in a real hospital pharmacy.

Sources

1. 1Cancer Statistics, 2020: Report From National Cancer Registry Programme, India — JCO Global Oncology / ICMR-NCDIR
2. 2Govt approves price hike for cancer drugs amid nationwide shortage — Business Standard, reporting NPPA notification dated 11 June 2026
3. 3NPPA has put a cap on Trade Margin of 42 select non-scheduled anti-cancer medicines under 'Trade Margin Rationalization' Approach — Press Information Bureau, Government of India
4. 4Development and Implementation of a Regional Program for the Safe Handling of Hazardous Drugs by Hospital Pharmacies — PMC, National Institutes of Health
5. 5Guidelines for Management of Healthcare Waste as per Bio-Medical Waste Management Rules — Central Pollution Control Board, Government of India
6. 6Generic Anticancer Drugs of the Jan Aushadhi Scheme in India and Their Branded Counterparts: The First Cost Comparison Study — Cureus / PMC, National Institutes of Health
7. 7Pradhan Mantri Bhartiya Janaushadhi Pariyojana — Department of Pharmaceuticals, Government of India
8. 825 Transformative Years of Biosimilars — BioSpectrum India, citing CDSCO approval data
9. 9National Pharmaceutical Pricing Authority — ceiling prices of scheduled formulations under DPCO 2013
10. 10Central Drugs Standard Control Organisation — Drugs and Cosmetics Act 1940 and Rules 1945

This article is for informational purposes and is not a substitute for professional medical advice. Consult a treating oncologist about chemotherapy regimens.